💊 SNRI vs SSRI Selection Simulator

Assessing the Symptom Profile

Baseline depression and anxiety symptoms are gathered before drug class choice.

• PHQ-9: Screening tool (depression severity scale)
• ~60%: Comorbid anxiety (of MDD patients)
• 2: First-line classes (SSRI, SNRI)
• 4–6 wk: Response window (typical trial length)

Intake assessment basics

Symptom domains scored: mood, pain, energy, anxiety, tolerability.

Why class choice matters

Mechanism overlap with symptom domain improves early response odds.

Comorbid Chronic Pain — Dual Mechanism Advantage

Norepinephrine reuptake blockade adds descending pain-modulation benefit.

• FDA-approved: SNRI pain indication (duloxetine, fibromyalgia)
• ~6: NNT neuropathic pain (duloxetine vs placebo)
• 2: Dual receptor targets (SERT + NET)
• high: Pain-mood overlap (shared descending pathways)

Descending pain modulation

Norepinephrine strengthens spinal inhibitory pain circuits.

Clinical pain indications

Duloxetine approved for neuropathic pain and fibromyalgia.

Low Energy, Anhedonia, and Motivation Deficit

Norepinephrine component supports alertness, drive, and motivation.

• ~35%: Anhedonia prevalence (of MDD presentations)
• arousal: NE role (alertness, motivation circuits)
• dose-dependent: Venlafaxine dose effect (NE activity rises >150mg)
• faster: Fatigue improvement (vs SSRI monotherapy)

Norepinephrine and drive

NE reuptake blockade lifts energy, focus, and motivation.

Dose-dependent NE activity

Higher venlafaxine doses meaningfully engage the NE transporter.

High Anxiety and GI Sensitivity — Favoring SSRI

SSRIs are typically better tolerated with fewer noradrenergic effects.

• SNRI > SSRI: BP elevation risk (dose-dependent, venlafaxine)
• both classes: GI side effects (SSRI often milder)
• SSRI: Anxiety first-line (per major guidelines)
• higher: Discontinuation symptoms (short half-life SNRIs)

Noradrenergic side effects

Elevated BP, sweating, and jitteriness track NE activity.

Tolerability in anxious patients

SSRIs favored when tolerability and GI sensitivity dominate.

Weighted Outcome — Combining the Symptom Profile

Pain, energy, and anxiety weights combine into one lean score.

• 3: Decision inputs (pain, energy, anxiety weights)
• % lean: Output (SNRI vs SSRI)
• ~60–70%: Shared response rate (either class, 6–8 wk)
• ~30%: Switch rate (require class change)

Combining weighted domains

Each domain nudges the needle toward SNRI or SSRI.

Individualized, not absolute

Final choice still needs full clinical judgment and history.

Placeholder: shared decision-making with the patient remains essential.